Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the fifth most common cancer worldwide. HCC is recognized as the fourth most common cause of cancer related deaths worldwide due to the lack of effective early diagnostic tools, which often leads to individuals going...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Gastrointestinal Disorders |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2624-5647/2/4/42 |
| _version_ | 1797545142970744832 |
|---|---|
| author | Bryan Mckiver Mohamad Imad Damaj Devanand Sarkar |
| author_facet | Bryan Mckiver Mohamad Imad Damaj Devanand Sarkar |
| author_sort | Bryan Mckiver |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the fifth most common cancer worldwide. HCC is recognized as the fourth most common cause of cancer related deaths worldwide due to the lack of effective early diagnostic tools, which often leads to individuals going undiagnosed until the cancer has reached late stage development. The current FDA approved treatments for late stage HCC provide a minimal increase in patient survival and lack tumor specificity, resulting in toxic systemic side effects. Gene therapy techniques, such as chimeric antigen receptor (CAR)-T Cells, viral vectors, and nanoparticles, are being explored as novel treatment options in various genetic diseases. Pre-clinical studies using gene therapy to treat in vitro and in vivo models of HCC have demonstrated potential efficacy for use in human patients. This review highlights genetic targets, techniques, and current clinical trials in HCC utilizing gene therapy. |
| first_indexed | 2024-03-10T14:11:17Z |
| format | Article |
| id | doaj.art-fbab13648dae43b18928b5e0e7682b64 |
| institution | Directory Open Access Journal |
| issn | 2624-5647 |
| language | English |
| last_indexed | 2024-03-10T14:11:17Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gastrointestinal Disorders |
| spelling | doaj.art-fbab13648dae43b18928b5e0e7682b642023-11-21T00:13:24ZengMDPI AGGastrointestinal Disorders2624-56472020-12-012446948010.3390/gidisord2040042Assessment of Current Gene Therapy Practices in Hepatocellular CarcinomaBryan Mckiver0Mohamad Imad Damaj1Devanand Sarkar2Department of Pharmacology and Toxicology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USADepartment of Pharmacology and Toxicology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USADepartment of Human and Molecular Genetics, Massey Cancer Center, VCU Institute of Molecular Medicine (VIMM), Virginia Commonwealth University, Richmond, VA 23298, USAHepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the fifth most common cancer worldwide. HCC is recognized as the fourth most common cause of cancer related deaths worldwide due to the lack of effective early diagnostic tools, which often leads to individuals going undiagnosed until the cancer has reached late stage development. The current FDA approved treatments for late stage HCC provide a minimal increase in patient survival and lack tumor specificity, resulting in toxic systemic side effects. Gene therapy techniques, such as chimeric antigen receptor (CAR)-T Cells, viral vectors, and nanoparticles, are being explored as novel treatment options in various genetic diseases. Pre-clinical studies using gene therapy to treat in vitro and in vivo models of HCC have demonstrated potential efficacy for use in human patients. This review highlights genetic targets, techniques, and current clinical trials in HCC utilizing gene therapy.https://www.mdpi.com/2624-5647/2/4/42HCCgene therapyclinical trialsCAR-Tvirusesnanoparticles |
| spellingShingle | Bryan Mckiver Mohamad Imad Damaj Devanand Sarkar Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma Gastrointestinal Disorders HCC gene therapy clinical trials CAR-T viruses nanoparticles |
| title | Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma |
| title_full | Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma |
| title_fullStr | Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma |
| title_full_unstemmed | Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma |
| title_short | Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma |
| title_sort | assessment of current gene therapy practices in hepatocellular carcinoma |
| topic | HCC gene therapy clinical trials CAR-T viruses nanoparticles |
| url | https://www.mdpi.com/2624-5647/2/4/42 |
| work_keys_str_mv | AT bryanmckiver assessmentofcurrentgenetherapypracticesinhepatocellularcarcinoma AT mohamadimaddamaj assessmentofcurrentgenetherapypracticesinhepatocellularcarcinoma AT devanandsarkar assessmentofcurrentgenetherapypracticesinhepatocellularcarcinoma |